Psilocybin Shows Promise for Treatment-Resistant Depression in NHS Trial

A Phase 2 NHS trial, published in Nature Medicine, found that a single 25-mg dose of psilocybin, combined with psychological support, significantly reduced depressive symptoms in individuals with treatment-resistant major depressive disorder. This randomized, double-blind, placebo-controlled study suggests the potential efficacy and feasibility of psilocybin-assisted therapy within public healthcare. The findings could offer a new therapeutic avenue for a challenging condition.